Table II.

Multivariate Cox regression analyses for progression-free survival and overall survival in patients from the matched dataset.

A, Progression-free survival
Variables	HR (95% CI)	P-value
Groups
Chemotherapy-bevacizumab vs. chemotherapy alone	0.48 (0.27–0.85)	0.011
Age, years
≤60 vs. >60	0.95 (0.49–1.88)	0.892
Sex
Female vs. male	0.82 (0.34–1.97)	0.656
Smoking history
Current/previous vs. never	1.15 (0.48–2.77)	0.753
Histology
Adenocarcinoma vs. squamous cell/adenosquamous carcinoma	1.25 (0.47–3.36)	0.655
EGFR mutation status
Wild-type/unknown vs. mutant type	0.74 (0.41–1.36)	0.333
Number of prior regimens
≤3 vs. >3	1.06 (0.57–1.98)	0.858
Chemotherapy regimen		0.326
Gemcitabine	Ref.
Pemetrexed	0.50 (0.21–1.24)	0.137
Paclitaxel	1.42 (0.54–3.77)	0.481
Docetaxel	1.31 (0.58–2.97)	0.511
B, Overall survival
Variables	HR (95% CI)	P-value
Group
Chemotherapy-bevacizumab vs. chemotherapy alone	0.53 (0.26–1.07)	0.076
Age, years
≤60 vs. >60	4.19 (1.17–14.97)	0.027
Sex
Female vs. male	1.30 (0.36–4.74)	0.694
Smoking history
Current/previous vs. never	3.32 (0.86–12.76)	0.081
Histology
Adenocarcinoma vs. squamous cell/adenosquamous carcinoma	1.33 (0.29–6.11)	0.711
EGFR mutation status
Wild-type/unknown vs. mutant type	1.10 (0.51–2.37)	0.812
Number of prior regimens
≤3 vs. >3	1.05 (0.49–2.26)	0.908
Chemotherapy regimen		0.064
Gemcitabine	Ref.
Pemetrexed	0.19 (0.05–0.84)	0.029
Paclitaxel	0.25 (0.05–1.24)	0.090
Docetaxel	0.57 (0.21–1.57)	0.275

EGFR, epidermal growth factor receptor; HR, hazard ratio; CI, confidence interval; Ref, reference.